Fujifilm : 1st Quarter ended June 30, 2023 Earnings Presentation
August 09, 2023 at 02:19 am EDT
Share
Earnings Presentation Financial Results for Q1 FY2023
August 9, 2023
Forward-looking statements, such as those relating to earnings forecasts and other projections contained in this material, are management's current assumptions and beliefs based on currently available information. Such forward-looking statements are subject to a number of risks, uncertainties, and other factors. Accordingly, actual results may differ materially from those projected due to various factors.
Agenda
Consolidated Financial Results for Q1 FY2023 (April to June 2023)
Earnings Highlights and Key Points for Q1 FY2023
Teiichi Goto, President and CEO, Representative Director,
FUJIFILM Holdings Corporation
Financial Results for Q1 FY2023 and Business Summary by Operating Segment
Masayuki Higuchi, CFO, Director and Corporate Vice President, FUJIFILM Holdings Corporation
FY2023 (The Fiscal Year Ending March 2024)
3
Financial Forecast for FY2023
Masayuki Higuchi, CFO, Director and Corporate Vice President,
Revenue increased mainly due to strong sales in Medical Systems and Imaging, and the impact of exchange rates.
Operating income rose mainly due to surging revenue from Imaging, despite a stagnant semiconductor market and other factors.
Net income attributable to FUJIFILM Holdings increased due to valuation gains on marketable and investment securities.
Full-year Forecast for FY2023
Revenue
Operating income
Net income
attributable to FUJIFILM Holdings
Record high
Record high
Record high
¥2,950.0 billion
¥290.0 billion
¥225.0 billion
(Announced on May 10, 2023)
〉 Full-year forecast remains unchanged from the previous forecast, aiming to achieve record-high revenue and profit. 〉 Annual dividend is planned to be ¥150 per share, marking the 14th consecutive annual increase.
From FY2023, revenue and operating income from the non-destructiveinspection equipment business are reclassified from the Materials segment to the Healthcare segment. The information for FY2022 has been restated in line with the above change in the segmentation.
Earnings Highlights
Highlights
Key Points
Q1 FY2023
FY2023
Appendix
Key Topics for Q1 FY2023 1/3
Medical Systems
Reorganization of group companies in Japan has started in the current fiscal year to maximize Group synergies with FUJIFILM Healthcare Corporation.*¹ We will rapidly build a robust business structure based on our Group's further enhanced collective capabilities, with the aim of achieving ¥1.0 trillion in revenue in FY2030.
FY2020
Revenue
¥349.0 billion
*¹ Established through the acquisition of
the diagnostic imaging-related business
STEP 1
of Hitachi, Ltd. in March 2021
Creating development synergies
Launch of CTs and ultrasound diagnostic systems with AI- based functions
Integrated local subsidiaries in Asia-Pacific and Europe
Progressing
as planned
*2:
FY2021
Revenue
¥533.8 billion
STEP 3
FY2023
to FY2024
Revenue forecast
¥650.0 billion
Creating sales and manufacturing synergies
Started cross-selling
Integrated manufacturing companies in Japan
Integrated sales subsidiaries in the U.S.
STEP 2
FY2022
Revenue*²
¥621.8 billion
Expanding Group synergies
･Launched X-ray diagnostic, fluoroscopic imaging systems
･Function-based reorganization of group companies in Japan (planned for completion in summer 2024)
Consolidation of business strategy planning and R&D functions
Consolidation of sales and maintenance service functions
Fujifilm Holdings Corporation published this content on 09 August 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 August 2023 06:18:10 UTC.
Fujifilm Holdings Corporation specializes in the manufacturing and marketing of printing, imaging and photography materials and equipment. Net sales break down by activity as follows:
- sale of printers and photocopiers (42.7%);
- sale of medical imaging equipment (41.4%): digital endoscopes, digital mammography devices, radiologic tables, ultrasound scan systems, etc. The group also develops pharmaceutical products development (generic drugs, health products, etc.) and design of graphic arts materials activities;
- sale of photography equipment (15.9%): digital cameras, bridges, lens, color negative films, films development materials, etc.
Net sales are distributed geographically as follows: Japan (48.7%), Americas (18.7%), Europe (10.1%) and other (22.5%).
FUJIFILM HOLDINGS CORPORATION 
